{"title":"Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa","authors":"Kazuki Fujimoto , Narumi Maki , Daisuke Hashiba , Toshifumi Maeyama , Ryosuke Nakagawa , Hajime Arai , Seiji Ohtori","doi":"10.1016/j.afos.2023.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.</div></div><div><h3>Methods</h3><div>In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.</div></div><div><h3>Results</h3><div>BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.</div></div><div><h3>Conclusions</h3><div>Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"9 4","pages":"Pages 137-141"},"PeriodicalIF":2.8000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis and Sarcopenia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405525523000687","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.
Methods
In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.
Results
BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.
Conclusions
Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.
Osteoporosis and SarcopeniaOrthopedics, Sports Medicine and Rehabilitation, Endocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Geriatrics and Gerontology
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
